Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Short Interest Down 18.2% in June

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totalling 506,400 shares, a decline of 18.2% from the May 30th total of 619,200 shares. Based on an average trading volume of 590,300 shares, the days-to-cover ratio is presently 0.9 days. Currently, 4.1% of the company’s stock are sold short.

A number of brokerages have recently issued reports on CYCC. Zacks Investment Research raised HANNOVER RUECK/S from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. HC Wainwright reaffirmed a “buy” rating on shares of Cyclacel Pharmaceuticals in a research report on Wednesday, May 15th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Resverlogix in a research report on Thursday, May 23rd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $5.50.

Shares of NASDAQ CYCC remained flat at $$0.61 during midday trading on Friday. The stock had a trading volume of 26,421 shares, compared to its average volume of 80,536. The stock has a market cap of $10.49 million, a P/E ratio of -0.98 and a beta of 2.94. Cyclacel Pharmaceuticals has a twelve month low of $0.51 and a twelve month high of $1.87. The stock has a 50-day simple moving average of $0.59. The company has a quick ratio of 8.09, a current ratio of 8.09 and a debt-to-equity ratio of 0.08.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.04. As a group, sell-side analysts predict that Cyclacel Pharmaceuticals will post -0.63 earnings per share for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

See Also: How to Trade Using Analysts Ratings

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.